The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021…
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Six of these have been filed with a form of expedited regulatory review, including Breakthrough designation, Priority Review or Fast Track status, four of them are biologicals and four are for cancer. Two are also first in class.
Ranked by highest sales forecast for 2021, the expected blockbuster 2017 launches are Roche’s Ocrevus (ocrelizumab) for multiple sclerosis (MS), Regeneron and Sanofi’s Dupixent (dupilumab) for allergic conditions, AstraZeneca’s durvalumab for cancer, Novo Nordisk’s semaglutide for type 2 diabetes, Eli Lilly and Incyte’s Olumiant (baricitinib) for rheumatoid arthritis (RA), Novartis’ ribociclib for cancer, Merck Serono and Pfizer’s avelumab for cancer and Tesaro’s niraparib for cancer. Kite Pharma’s KTE-C19 for haematological cancer, while not yet quite reaching blockbuster status, is included in this report for the interest it is generating among industry observers.
Topping the ranking for 2017’s blockbusters by 2021 sales is Roche’s Ocrevus, which is expected to materially disrupt the MS market when it launches in 2Q17. The MS market is a fascinating one, as it has been transformed by oral options since 2010, yet older injectable mainstays such as the interferons have ceded market share relatively slowly. The first generics (eg Momenta’s glatiramer generic, Glatopa) have not altered the market to much extent, but the first oral generics are on the horizon which will have a greater impact. Despite this maturing market, significant need remains for treatment options with novel mechanisms and an optimal combination of improved potency, tolerability and convenience.
Ocrevus is a first-in-class anti-CD20 antibody which met its endpoints in two pivotal trials in relapsing remitting MS (OPERA 1 & 2) according to data reported in 2015. Compared with Rebif (recombinant interferon beta-1a), Ocrevus reduced the annualised relapse rate by 47% at week 96, with secondary endpoints also met, including delayed confirmed disability progression and reduced new brain lesions; safety and tolerability data were favourable. Perhaps more interestingly, the drug is also the first ever to prove effective in primary progressive MS, as seen in the ONTARIO trial where the risk of progression of clinical disability was reduced by 24%. Initial market share gains are likely in the second line behind oral options and in severe patients on Tysabri (natalizumab) who are at risk of progressive multifocal leukoencephaolopathy, but adoption in naive patients may be expected in the medium term as prescriber familiarity builds.
Regeneron’s IL-4 alpha subunit inhibitor Dupixent was successful in several phase III studies in its first development setting of atopic dermatitis (AD), and is expected to launch in 2Q17 shortly after its PDUFA date of March 29. In the SOLO-1 & 2 trials in mild to moderate AD patients inadequately controlled with topical medications, 37 and 36% patients saw clearance or near clearance of skin lesions at 16 weeks, respectively. Co-administration with a corticosteroid was also superior to corticosteroid therapy alone (39 versus 12%).
These strong short-term outcomes, combined with the lack of existing treatment options, are expected to drive wide adoption, despite the unfamiliar mechanism of action. A phase II trial in paediatric patients is also completing; unmet need in this setting is particularly notable, and approval in paediatrics would drive upside. Benefit has also been seen in phase III trials in eosinophilic asthma, although severe asthma is a competitive space and the impact of approval in this setting does not appear clear cut.
3. Durvalumab for cancer
The first BLA filing for AstraZeneca’s PD-L1 antibody durvalumab was accepted in December 2016 in bladder cancer, and through Priority Review it is now expected to launch in 2H17. While the drug will provide a meaningful treatment option in the bladder cancer setting, it is in lung cancer where the most notable sales are expected.
AstraZeneca had initially aimed to be entering the lung cancer market in 2016, through its ATLANTIC study in the third-line non-small-cell lung cancer (NSCLC) setting, but the company was delayed when monotherapy data were not strong enough to warrant continued development in the third line. However, positive early-stage data in the first line led to the initiation of the MYSTIC phase III trial in front-line NSCLC, comparing the drug in combination with tremelimumab against standard of care. A read out for MYSTIC is expected in mid-2017, which could set the stage for a filing by the end of the year. The failure of heavyweight competitor Opdivo (nivolumab) in first-line NSCLC in 2016, together with Merck apparently playing it safe with Keytruda (pembrolizumab) by seeking approval in the first line only in high PD-L1 expressers could mean big wins for durvalumab, despite being later to market. Therefore much hinges on MYSTIC, and although many view the trial as riskier than typical phase III trials, success would bring the company one of its major growth drivers for the coming years.
4. Semaglutide for diabetes
Novo Nordisk’s weekly GLP1 analog semaglutide was filed in December 2016 based on positive data from the SUSTAIN program in type 2 diabetes, and launch is expected by year-end 2017. SUSTAIN data showed a potent ability to control HbA1 across all stages of the treatment paradigm, as well as a robust weight-loss effect with statistical superiority to Januvia (sitagliptin) in SUSTAIN-2, to Bydureon (controlled-release exenatide) in SUSTAIN-3 and to Lantus (insulin glargine) in SUSTAIN-4. It also improved cardiovascular outcomes, according to the SUSTAIN-6 trial, reducing stroke risk by 39% and myocardial infarction risk by 26%.
Assuming approval, semaglutide will be the fourth weekly GLP-1 analog to market, behind Trulicity (dulaglutide), Tanzeum (albiglutide) and Bydureon, however it is Novo’s once daily oral formulation of the drug which may be expected to be practice changing in type 2 diabetes. After encouraging phase II data, Novo Nordisk began the phase III PIONEER studies of oral semaglutide in 2016, the first of which is expected to read out in 2018. Success could mean earlier switching from small molecule oral antidiabetics, which would have significant market implications.
Positive data have been reported in methotrexate-naive patients (RA-BEGIN), DMARD failures (RA-BEAM, RA-BUILD) and inadequate responders to anti-TNFs (RA-BEACON), and the drug has proven superior to Humira (adalimumab) on several metrics. Market share gain may be initially expected to come at the expense of other JAK inhibitors, primarily Xeljanz (tofacitinib), but with building prescriber familiarity the drug could move ahead of TNF inhibitors in the treatment paradigm.
The drug is behind Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib), a strong competitor which was launched in early 2015. Novartis reported pivotal data from its MONALEESA-2 trial of ribociclib in October 2016, which showed an overall response rate of 41% when dosed with letrozole versus 28% for letrozole alone. In terms of clinical activity, ribociclib appears similar to Ibrance, and with such similar profiles, it may be difficult for ribociclib to displace Ibrance. To help differentiate the drug, Novartis has initiated MONALEESA-7 to evaluate ribociclib plus tamoxifen and goserelin in pre- and peri-menopausal women, which is a unique indication setting from any other CDK4/6 inhibitor in development.
7. Avelumab for cancer
Pfizer’s avelumab is a fully human anti-PDL1 antibody expected to enter the market in 3Q17 in its first cancer setting of second-line metastatic Merkel cell carcinoma; the drug has shown a tumour response in 31.8% of patients which is a potential breakthrough in this challenging disease. However, as the leading checkpoint inhibitor in ovarian cancer and the first to enter phase III trials in this setting, it is this market that is expected to garner most sales.
Ovarian cancer presents the first commercial opportunity for TESARO’s PARP inhibitor niraparib, and an NDA was accepted for Priority Review in December 2016 directing to a 3Q17 launch. The drug succeeded in the second-line maintenance setting in the phase III NOVA trial, with a reduction in risk of progression versus placebo of 73% and a median progression-free survival (PFS) of 21 versus 5.5 months. Notably, niraparib also improved PFS in BRCA-negative patients (12.9 versus 3.8 months), which would allow use in a much larger population than targeted by competitor Lynparza (olaparib). A study in front-line platinum responders (QUADRA) is also ongoing.
9. KTE-C19 in cancer
T-cells engineered against cancer antigens (CAR-T) are generating perhaps the most excitement in the industry at the moment. Kite Phama is hopeful it can be the first company to bring a CAR-T therapy to market with KTE-C19, following the initiation of a rolling filing in aggressive B-cell non-Hodgkin’s lymphomas (NHL) in December 2016, and the company hopes to launch the drug at the very end of 2017.
KTE-C19 is an autologous T-cell therapy expressing a cancer antigen specific for CD19, which is a B cell marker. The pivotal ZUMA-1 study supporting the submission enrolled patients with chemorefractory diffuse large B-cell lymphoma, transformed follicular lymphoma and primary mediastinal B-cell lymphoma – three subtypes of aggressive NHL. ZUMA-1 demonstrated a striking objective response rate of 82% and a complete remission rate of 54%, when dosed following a conditioning regimen of fludarabine and cyclophosphamide. A number of other studies are ongoing or planned in mantle cell lymphoma (ZUMA-2), adult and paediatric acute lymphocytic leukaemia (ZUMA-3 & 4), indolent NHL (ZUMA-5) and chronic lymphocytic leukaemia (ZUMA-8). Early market access may depend initially on building scientific awareness among prescribers, and an efficient and consistent manufacturing process.
Alexandra Kibble is a senior editor within the Clarivate Analytics Cortellis team. She has a PhD in neurology, and has built nearly 20 years of industry experience through working on the varied pharmaceutical intelligence products within the company. Her work currently involves conducting market-based analyses and sales forecasting for strategic drugs, and her main interests lie in international pricing and reimbursement, and market access strategies.
I am a patient of lung fibrosis from developing country .
Developed countries have estimated 600000 new patients every year
This does not include India ,china , Far East ( except Japan , South Korea )
Middle East and afrika .
Under developed countries and even developing countries has neither resources and expertise to diagnose the disease 100 percent advance stage in
95 percent of population and remote areas where even primary healthcare facilities not available .
Recent study conducted by usa medical Authourities that Middle East countries will have approximately 60 millions patients of lung diseases by 2020.
This sector is ignored by MNC and Govt of advanced countries .
This segment can give market of usd 50 billions by 2025
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
I am a patient of lung fibrosis from developing country .
Developed countries have estimated 600000 new patients every year
This does not include India ,china , Far East ( except Japan , South Korea )
Middle East and afrika .
Under developed countries and even developing countries has neither resources and expertise to diagnose the disease 100 percent advance stage in
95 percent of population and remote areas where even primary healthcare facilities not available .
Recent study conducted by usa medical Authourities that Middle East countries will have approximately 60 millions patients of lung diseases by 2020.
This sector is ignored by MNC and Govt of advanced countries .
This segment can give market of usd 50 billions by 2025